Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation

Area of Science:

• Oncology
• Vascular Biology
• Cancer Therapy

Background:

• Vascular targeting agents (VTAs) aim to inhibit tumor growth by disrupting blood vessels.
• Current VTAs include anti-angiogenesis agents and vascular disrupting agents.
• Despite therapeutic potential, complete tumor eradication and cure remain challenging due to treatment resistance.

Purpose of the Study:

• To highlight the critical role of tumor rim cells in determining the success of vascular targeting therapies.
• To review single and combination treatments that target tumor rim cells effectively.
• To explore strategies for eliminating residual rim cells for permanent tumor ablation.

Main Methods:

• Literature review of current vascular targeting strategies.
• Analysis of preclinical and clinical data on tumor recurrence and resistance.
• Discussion of the biology and survival mechanisms of tumor rim cells.

Main Results:

• Tumor rim cells are identified as a key factor in the refractoriness of tumors to vascular targeting agents.
• Specific treatment approaches targeting these rim cells show promise for long-lasting tumor cure.
• Understanding rim cell behavior is essential for developing more effective therapies.

Conclusions:

• Targeting tumor rim cells is critical for overcoming resistance and achieving durable responses with vascular targeting agents.
• Future strategies should focus on eliminating residual rim cells to achieve complete tumor ablation.
• Further research into the mechanisms of rim cell survival and contribution to refractoriness is warranted.